New York, NY -- (SBWIRE) -- 01/08/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Pluristem Therapeutics Inc (NASDAQ:PSTI), PDL BioPharma Inc (NASDAQ:PDLI), Dyax Corp (NASDAQ:DYAX), NovaGold Resources Inc. (USA) (NYSEMKT:NG)
Pluristem Therapeutics Inc (NASDAQ:PSTI) showed a volume of 1.53 million shares by the end of last trade whereas the average volume of the stock remained 199,985.00 shares. The stock opened the session at $4.12 but then moved to $4.11. At that price, the stock showed a positive performance of 4.31%. Pluristem Therapeutics Inc. (Pluristem) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from human placenta, a non-controversial, non-embryonic, adult stromal cell source. The placental adherent stromal cells (ASCs) are grown in the Company's PluriX three-dimensional (3-D) bioreactor, which imitates the natural microstructure of the body.
Will PSTI Continue To Move Higher? Find Out Here
PDL BioPharma Inc (NASDAQ:PDLI) opened the session at $8.72 and closed the session at $8.67. The stock showed a positive performance of 0.23% in previous trading session. PDL BioPharma, Inc. (PDL) is a is a biotech company. PDL is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The Company receives royalties based on sales of humanized antibody products marketed and may also receive royalty payments on additional humanized antibody products launched before final expiry in December 2014.
For How Long PDLI will fight for Profitability? Read This Trend Analysis report
Dyax Corp (NASDAQ:DYAX) opened the session at $7.64 and closed the session at $7.82. The stock showed a positive performance of 3.03% in previous trading session. The beta of the stock remained 1.69. Dyax Corp. (Dyax), is a biopharmaceutical company with two business elements: Angioedema Franchise and Phage Display Licensing and Funded Research Program. It is focused on identifying and developing treatments for patients who experience plasma kallikrein (bradykinin) mediated angioedema. The principal focus of Dyax is to identify, develop and commercialize treatments for conditions identified as plasma kallikrein (bradykinin) mediated angioedema, including hereditary angioedema (HAE), ACE inhibitor-induced angioedema (ACEI-AE) and angioedema of unknown origin, or idiopathic angioedema.
Why Should Investors Buy DYAX After The Recent Gain? Just Go Here and Find Out
NovaGold Resources Inc. (USA) (NYSEMKT:NG) the stock decreased -2.18% and finished the session at $2.69. Traded with volume of 1.51 million shares in the prior session and the average volume of the stock remained 1.75 million shares. The beta of the stock remained 0.72. NovaGold Resources Inc. (NovaGold) is engaged in the exploration and development of mineral properties. The Company has a portfolio of mineral properties located in Alaska, the United States and British Columbia, Canada. The Donlin Gold project in Alaska is held by a limited liability company owned equally by wholly owned subsidiaries of NovaGold and Barrick Gold Corporation (Barrick). The Galore Creek project is held by a partnership owned equally by wholly owned subsidiaries of NovaGold and Teck Resources Limited (Teck).
Will NG Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)